Loading stock data…
NEPH
$3.11-0.05 (-1.58%)
Market ClosedLast close May 1
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nephros, Inc. in the Healthcare sector is trading at $3.11. The stock is currently 52% below its 52-week high of $6.42, remaining 26.5% below its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why NEPH maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.11
Potential Downside
21.2%
Whystock Fair Value$2.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.82
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.70%
Volume
Today's trading volume
3,936
Recent News
3 Promising Penny Stocks With Market Caps Under $200M
Over the last 7 days, the market has remained flat, yet it is up 28% over the past year with earnings forecasted to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for growth at lower price points, especially when backed by strong balance sheets and solid fundamentals. This article explores several penny stocks that stand out as hidden gems, potentially offering both stability and upside in today's market landscape.
Nephros Inc (NEPH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Margin Pressures
Nephros Inc (NEPH) reports a 33% annual revenue increase, while navigating tariff impacts and expanding into non-medical markets.
Nephros (NEPH) Q4 2025 Earnings Call Transcript
Robert Banks: Thank you, Kirin. Clean water is essential for health care, hospitality, food services and everyday life. Together, these pillars are driving our growth and positioning Nephros as a leader in water safety solutions.
Nephros, Inc. Q4 2025 Earnings Call Summary
Moby summary of Nephros, Inc.'s Q4 2025 earnings call
Promising Penny Stocks To Consider In February 2026
As February begins, U.S. stock indexes have shown a strong start with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. While larger market trends capture headlines, investors often overlook smaller opportunities such as penny stocks, which despite their vintage name, continue to offer potential for significant returns when backed by solid financials. This article explores three promising penny stocks that combine balance sheet strength with...